Healthy Returns: Novo Nordisk's head of research and development previews the first-ever obesity pill
1. Novo Nordisk expects U.S. approval for a needle-free weight loss pill this year. 2. The oral semaglutide pill could provide substantial weight loss and cardiovascular benefits. 3. Pill's dietary dosage may pose theoretical concerns but likely manageable for patients. 4. Novo Nordisk aims to meet high demand with increased manufacturing capacity. 5. Competitors like Eli Lilly are also developing obesity pills but face challenges.